NOV 10, 2019 03:41 PM PST

Promising Results for New Vaccine Against Dengue Fever

WRITTEN BY: Annie Lennon

Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Although vaccines have been developed to tackle the condition, so far, they have been limited in efficacy. This may change however thanks to promising preliminary results from a new vaccine developed by Japanese pharmaceutical firm, Takeda. 

The first vaccine for the disease, known as Dengvaxia, was approved in 2016. Although effective in some cases, it has limited utility due to its reputation for increasing the risk of serious illness among people with no previous exposure to Dengue fever, and is thus only used on those who have already been infected with the virus. 

Unlike Dengvaxia, the new vaccine developed by Takeda seems to be effective for both those who have previously had Dengue Fever and those with no previous exposure. 

Based on a weakened form of the live virus, researchers compared the new drug to a placebo in a trial of over 20,000 children aged between 4 and 16 in 26 locations around Asia and Latin America. With each child receiving two doses of the vaccine three months apart, so far results from a one-year follow up after the second dose show the vaccine to be 80.2% effective (Steenhuysen: 2019). 

Out of the four versions of the Dengue virus in circulation, the new vaccine appears to offer good protection against one type, and partial protection against two others. Although exciting news for regions where this condition is widespread and researchers alike however, a three-year follow-up is still necessary to confirm its protective results are stable (Wong: 2019). 

According to Duane Gubler at Duke-NUS Medical, Singapore, a patent holder of the new vaccine, “If these results hold during long-term follow-up and if the vaccine shows a significant reduction in severe disease, this vaccine, if used properly, could have a major impact on our ability to prevent and control the pandemic of dengue currently ravaging the world (ibid).”,

Rajeev Venkayya, president of Takeda added, “While more data is needed to fully understand the safety and efficacy profile of TAK-003, these findings strongly suggest that it could help address the massive global burden of dengue in all populations. We look forward to sharing more data in the coming weeks, and engaging health authorities and the scientific, public health and medical communities on these findings, priorities for future evidence generation, and ways we can work together to maximise the reach and impact of this vaccine upon licensure (BL: 2019).”

 

Sources 

 

Steenhuysen, Julie: Reuters

Wong, Sam: New Scientist

BL: The Hindu Business Line

 

About the Author
  • Writer with a keen interest in genetics, psychology, health and everything in between. Currently focused on the interplay of genetics and society to understand how to create meaningful interactions and environments.
You May Also Like
DEC 10, 2019
Drug Discovery & Development
DEC 10, 2019
Adderall is Almost Identical to Crystal Meth
Adderall has a reputation for giving people a feeling of euphoria, increasing energy levels and enhancing abilities to focus and concentrate. And coinciden...
DEC 10, 2019
Immunology
DEC 10, 2019
Treating Celiac Disease May Be Possible
Delivering gluten to the body in a friendly, harmless package may be the way for people with celiac disease to finally have a sandwich again. A new clinica...
DEC 10, 2019
Microbiology
DEC 10, 2019
Antibody Discovered That May be the Key to a Universal Flu Vaccine
Instead of designing a new flu vaccine every year, researchers have made a breakthrough that may lead to a single vaccine that protects against all strains....
DEC 10, 2019
Cell & Molecular Biology
DEC 10, 2019
New Insight Into Chronic Pain May Help Create Novel Therapeutics
Acute pain can progress to chronic pain, which can cause other problems including depression, loss of motivation and sensory dysfunction....
DEC 10, 2019
Health & Medicine
DEC 10, 2019
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
DEC 10, 2019
Neuroscience
DEC 10, 2019
Single Dose Ketamine Could Rewire Alcohol, Drug Dependance
Presentation by Tobias Stephenson about previous research exploring ketamine as an addiction treatment.    Researchers at University College Lond...
Loading Comments...